A Review on Huntingtons Disease
Keywords:
Abstract
Abstract- Neurodegenerative diseases exemplified by Alzheimer’s and Huntington disease are characterized by the progressive neuropsychiatric dysfunction and loss of specific neuronal subtypes. Huntington’s disease (HD) is a devastating neurodegenerative disorder that occurs in patients with a mutation in the huntingtin or IT15 gene. Patients are plagued by early cognitive signs, motor deficits, and psychiatric disturbances. Symptoms are attributed to cell death in the striatum and disruption of cortical–striatal. Mechanisms of cell death are unclear, but processes involving mitochondrial abnormalities, excitotoxicity, and abnormal protein degradation have been implicated. Many factors likely contribute to neuron death and dysfunction and this has made it difficult to systematically address the pathology in HD. Pharmaceutical therapies are commonly used in patients to treat disease symptoms. These have limited benefit and do not address the inexorable disease progression. Several neuroprotective therapies are being evaluated in animal models of HD as well as in clinical trials. Similarly, cell replacement strategies such as fetal transplantation have been used in the clinic with minimal success, making future cell replacement strategies such as stem cell therapy uncertain. This review describes the disease pathology and neurochemistry of HD and addresses many of the past and emerging therapeutic strategies.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
M. Novak, S. Tabrizi (2010) Huntington's disease.
A. Sawa, T. Tomoda, B-I Bae (2003) Mechanisms of neuronal cell death in Huntington's disease Cytogenet Genome Res. 100(1-4), 287-295. https://doi.org/10.1159/000072864
Z. Qin, Lgu Zhen (2004) Huntingtin processing in pathogenesis of Huntington's disease Acta Pharmacol Sin. 25, 1243-1249.
Jelliffe SE (1908) A contribution to the history of Huntington's chorea: a preliminary report Neurographs. 1, 116-1124.
A. Qrbeck (1959) An early description of Huntington's chorea Medical History. 3(2), 165-168. https://doi.org/10.1017/s0025727300024492
J. Klein, Guthrie (1981) A life.
Peters. Harper (1986) The epidemiology of Huntington's disease Hum Genet. 89(4), 365-376. https://doi.org/10.1007/bf00194305
S. Jha, R. Patel (2004) Some observations on the spectrum of dementia. 52, 213-214.
Jeremy Van Raamsdonk, Jacqueline Pearson, Elizabeth Slow, Sazzad Hossain, Blair Leavitt, Michael Hayden (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease J Neurosci. 25(16), 4169-4180. https://doi.org/10.1523/jneurosci.0590-05.2005
Delval A, Krystkowiak P, Blatt JL (2006) Role of hypokinesia and bradykinesia in gait disturbances in Huntington's disease- A biomechanical study J Neurol. 253(1), 73-80. https://doi.org/10.1007/s00415-005-0929-2
P. Naarding, Hph Kremer, F. Zitman (2001) Huntington's disease: a review of the literature on prevalence and treatment of neuropsychiatric phenomena. 16(8), 439-445. https://doi.org/10.1016/s0924-9338(01)00604-6
Klivenyi P, Bende Z, Hartai Z (2006) Behaviour changes in a transgenic model of Huntington's disease. 169(1), 137-141. https://doi.org/10.1016/j.bbr.2006.01.003
Nehl Paulsen JS, Hoth K.F (2005) Depression and stages of Huntington's disease J Neuropsychiatry Clin Neurosci. 17(4), 496-502. https://doi.org/10.1176/jnp.17.4.496
Cummings JL (1995) Behavioral and psychiatric symptoms associated with Huntington's disease. 65, 179-186.
Baudic S, Maison P, Dolbeau G (2006) Cognitive Impairment Related to Apathy in Early Huntington's disease Dement Geriatr Cogn Disord. 21(5-6), 316-321. https://doi.org/10.1159/000091523
Astri Lundervold, Ivar Reinvang, Arvid Lundervold (1994) Characteristic patterns of verbal memory function in patients with Huntington's disease Scand J Psychol. 35(1), 38-47. https://doi.org/10.1111/j.1467-9450.1994.tb00931.x
K. Anderson, F. Marshall (2005) Behavioral symptoms associated with Huntington's disease Adv Neurol. 96, 197-208.
E. Garrett, M. Crutcher (1990) Functional architecture of basal ganglia circuits: Neuronal substrate of parallel processing Trends in Neuroscience. 13, 266-271.
Ann Graybiel (1990) Neurotransmitters and neuro modulators in the basal ganglia Trends in Neuroscience. 13(7), 244-254. https://doi.org/10.1016/0166-2236(90)90104-i
Susan Browne, Robert Ferrante, M. Beal (1999) Oxidative Stress in Huntington's Disease. 9(1), 147-163. https://doi.org/10.1111/j.1750-3639.1999.tb00216.x
Bjørnar Hassel, Ursula Sonnewald (1995) Selective inhibition of the tricarboxylic acid cycle of GABAergic neurons with 3-nitropropionic acid in vivo J Neurochem. 65(3), 1184-1191. https://doi.org/10.1046/j.1471-4159.1995.65031184.x
Reddy HP, Maya W, Danilo AT (1999) Recent advances in understanding the pathogenesis of Huntington's disease. 22, 248-254.
M. Beal (2000) Energetic in the pathogenesis of neurodegenerative disease. 23(7), 298-304. https://doi.org/10.1016/s0166-2236(00)01584-8
Gutekunst AC, Francine N, Hersch MS (2000) Recent advances in Huntington's disease Current Opinion in Neurology. 13(4), 445-450. https://doi.org/10.1097/00019052-200008000-00013
Hickey MA, Chesselet MF (2003) Apoptosis in Huntington's disease. 27, 255-265.
Rlm Faull, H. Waldvogel, Lfb Nicholson, Bjl Synek (1993) Chapter 7 The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat. 99, 105-123. https://doi.org/10.1016/s0079-6123(08)61341-2
Kleppner SR (2001) GABA signalling: therapeutic targets for epilepsy, Parkinson's disease and Huntington's disease. 5, 219-239.
M. Glass, M. Dragunow, Rlm Faull (2000) The pattern of neurodegeneration in Huntington's disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington's disease. 97(3), 505-519. https://doi.org/10.1016/s0306-4522(00)00008-7
Ann Graybiel (1990) Neurotransmitters and neuromodulators in the basal ganglia Trends in Neuroscience. 13(7), 244-254. https://doi.org/10.1016/0166-2236(90)90104-i
Steinbusch Teunissen CE, Angevaren M, spatial orientation (2001) Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. 105, 153-167.
B. Manyam, E. Giacobini, J. Colliver (1990) Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington's disease. 237, 281-284.
Caboche J, Charvin D (2006) Role of dopamine in Huntington's disease. 22, 115-127.
Amaal Starling, Véronique André, Carlos Cepeda, Marianne de Lima, Scott Chandler, Michael Levine (2005) Alterations in N-methyl- Daspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease J Neurosci Res. 82(3), 377-386. https://doi.org/10.1002/jnr.20651
The Huntington (1993) s Disease Collaborative Research Group: Novel genes containing a trinucleotide repeat that is expanded and unstable on Huntington. 72, 971-983.
Bao J, Sharp AH, Waster MV (1996) Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. 93, 5037-5047.
Thomas Arzberger, Klaus Krampfl, Susanne Leimgruber, Adolf Weindl (1997) Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease--an in situ hybridization study J Neuropathol Exp Neurol. 56(4), 440-454. https://doi.org/10.1097/00005072-199704000-00013
R. Kukreja, H. Kontos, M. Hess, E. Ellis (1986) PGH synthase and lipoxygenase generate superoxide in the presence of NADH or NADPH Circ Res. 59(6), 612-619. https://doi.org/10.1161/01.res.59.6.612
Leavitt RB, Wellington LC, Hayden RM (2007) Recent insights into the molecular pathogenesis of. 41(4), 294.
Huntington's disease (1999) 19, 385-395.
J. Hannan (2004) Huntington's disease: which drugs might help patients? I Drugs. 7, 351-358.
M. Verhagen, M. Morris, C. Farmer, M. Gillespie, K. Mosby, J. Wuu (2002) Huntington's disease: a randomized, controlled trial using the NMDAantagonist amantadine Neurology. 59, 694-699.
Bonelli MR, Gregor KW, Kapfhammer PH (2004) Huntington's disease: present treatments and future therapeutic modalities International Clinical Psychopharmacology. 19(2), 51-62. https://doi.org/10.1097/00004850-200403000-00001
L. Becker, R. Miguel, Jjf Ruzi (2003) The endocannabinoid system and Huntington's disease Current Drug Targets-CNS & Neurological Disorders. 2, 335-347.
Charity Aiken, Allan Tobin, Erik Schweitzer (2004) A cell-based screen for drugs to treat Huntington's disease Neurobiol Dis. 16(3), 546-555. https://doi.org/10.1016/j.nbd.2004.04.001
Karpuj MV, Becher MW, Springer JE (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease with administration of the transglutaminase inhibitor cystamine Nat Med. 8(2), 143-149. https://doi.org/10.1038/nm0202-143
Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. 6(7), 797-801. https://doi.org/10.1038/77528
Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E (2003) Minocycline inhibits caspaseindependent and -dependent mitochondrial cell death pathways in models of Huntington's disease Proc Natl Acad Sci USA. 100(18), 0483-1048. https://doi.org/10.1073/pnas.1832501100
Bodai Steffan JS, Poelman Pallos J, McCampbell A (2001) Histone deacetylase inhibitors arrest polyglutamine dependent neurodegeneration in Drosophila Nature. 413(6857), 739-743. https://doi.org/10.1038/35099568
Alexis-Pierre Bemelmans, Philippe Horellou, Laurent Pradier, Isabelle Brunet, Philippe Colin, Jacques Mallet (1999) Brain-derived neurotrophic factormediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer Hum Gene Ther. 10(18), 2987-2997. https://doi.org/10.1089/10430349950016393
J. Davis, J. Filoteo, W. Maddox (2001) A possible role of the striatum in linear and nonlinear category learning: evidence from patients with Huntington's disease. 123, 234-239.
G. Gardian, L. Vecsei (2004) Huntington's disease: pathomechanism and therapeutic perspectives. 111, 1485-1494.
P. Harjes, Wanker (2003) The hunt for huntingtin function: interaction partners tell many different stories. 28, 425-33.
Metzler (2001) HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. 276, 9271-6.
S. Waelter (2001) The huntingtin interacting protein HIP1 is a clathrin and alphaadaptin-binding protein involved in receptor-mediated endocytosis. 10, 1807-17.
Katharine Sugars, David Rubinsztein (2003) Transcriptional abnormalities in Huntington disease. 19(5), 233-238. https://doi.org/10.1016/s0168-9525(03)00074-x
D. Rigamonti Wild-type huntingtin protects from apoptosis upstream of caspase- 3.
Leavitt (2001) Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. 68, 313-24.
S. Li, Li, X. interactions (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's disease. 20, 146-54.
E. Bossy-Wetzel, R. Schwarzenbacher, Lipton (2004) Molecular pathways to neurodegeneration. 10(Suppl), 2-9.
Panov (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. 5, 731-6.
H. Rangone, S. Humbert, F. Saudou Huntington's disease: how does huntingtin, an anti-apoptotic protein, become toxic?.
Chen (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. 6(7), 797-801. https://doi.org/10.1038/77528
Ona (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease. 399, 263-267.
I. Sanchez Caspase-8 is required for cell death induced by expanded polyglutamine repeats.
C. Zuccato Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease.
C. Landles, Bates, G. Huntingtin (2004) Huntingtin and the molecular pathogenesis of Huntington's disease. 5, 958-63.
C. Wellington, B. Leavitt, M. Hayden (2000) Huntington disease: new insights on the role of huntingtin cleavage. 58, 1-17. https://doi.org/10.1007/978-3-7091-6284-2
Hackam (1998) The influence of huntingtin protein size on nuclear localization and cellular toxicity. 141, 1097-105.
S. Li, S. Lam, A. Cheng, Li (2000) Intranuclear huntingtin increases the expression of caspase-1 and induces apoptosis. 9, 2859-67.
L. Mende-Mueller, T. Toneff, S. Hwang, M. Chesselet, Hook (2001) Tissuespecific proteolysis of Huntingtin (htt) in human brain: evidence of enhanced levels of Nand C-terminal htt fragments in Huntington's disease striatum. 21, 1830-7.
Ho (2001) The molecular biology of Huntington's disease. 31(1), 3-14. https://doi.org/10.1017/s0033291799002871
M. Beal (2000) Energetics in the pathogenesis of neurodegenerative diseases. 23(7), 298-304. https://doi.org/10.1016/s0166-2236(00)01584-8
Bates, G. aggregation (2003) Huntingtin aggregation and toxicity in Huntington's disease. 361, 1642-4.
L. Jones (2002) The cell biology of Huntington's disease. 349-386.
C. Gutekunst, F. Norflus, S. Hersch The neuropathology of Huntington's disease.
R. Friedlander Apoptosis and caspases in neurodegenerative diseases. 348.
Rubinsztein (2002) Lessons from animal models of Huntington's disease. 18, 202-9.
The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. 72, 971-83.
E. Brouillet, F. Conde, M. Beal, P. Hantraye (1999) Replicating Huntington's disease phenotype in experimental animals. 59, 427-68.
W. Brennan, Bird Jr, E.D, Aprille (1985) Regional mitochondrial respiratory activity in Huntington's disease brain. 44, 1948-50.
D. Rubinsztein Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. 59, 30-40.
J. Vonsattel, DiFiglia (1998) Huntington disease. 57, 369-84.
DiFiglia (1995) Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. 14, 1075-1081.
Trottier (1995) Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. 378, 403-406.
Cheryl Wellington, Ryan Brinkman, John O'kusky, Michael Hayden (1997) Toward understanding the molecular pathology of Huntington's disease. 7(3), 979-1002. https://doi.org/10.1111/j.1750-3639.1997.tb00897.x
Åsa Petersén, Kevin Mani, Patrik Brundin (1999) Recent Advances on the Pathogenesis of Huntington's Disease. 157(1), 1-18. https://doi.org/10.1006/exnr.1998.7006
Dragunow In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes. 6.
C. Portera-Cailliau, J. Hedreen, D. Price, V. Koliatsos (1995) Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models. 15, 3775-87.
Thomas (1995) DNA end labeling (TUNEL) in Huntington's disease and other neuropathological conditions. 133, 265-72.
M. Hickey, Chesselet (2003) Apoptosis in Huntington's disease. 27, 255-65.
Y. Goldberg Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract.
T. Kiechle (2002) Cytochrome C and caspase-9 expression in Huntington's disease. 1, 183-195.
F. Nucifora (2001) Interference by Huntingtin and Atrophin-1 with CBP-Mediated Transcription Leading to Cellular Toxicity. 291, 2423-2428.
J. Vis Expression of apoptosis-related markers in human HD brains. 109.
Published
2018-02-14
Issue
Section
License
Copyright (c) 2018 Authors and Global Journals Private Limited

This work is licensed under a Creative Commons Attribution 4.0 International License.